SS 40 - H&N 2: Predicting the Future with Immunologic, Genomic, and Imaging Metrics

Moderator(s)

• 

  Michelle Echevarria, MD

  Moffitt Cancer Center
  Tampa, FL, United States
• 

  Jared Robbins, MD

  University of Arizona College of Medicine
  Tucson, AZ

Presentations:

• 5:15 PM – 5:25 PM ET

  Cellular Immune and Genomic Biomarkers in NRG-HN003, a Phase I Study Adding Pembrolizumab to Adjuvant Cisplatin and Radiation Therapy (CRT) in Pathologically High-Risk Head and Neck Cancer (HNSCC)
  

  Presenter: Julie Bauman, MD – George Washington University Cancer Center
• 5:25 PM – 5:35 PM ET

  Metrics Derived from Architecture of Tumor-Infiltrating Lymphocytes are Associated with Overall Survival in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Patients: Results from NRG/RTOG 0129 and
  

  Presenter: German Corredor, PhD, MS – Emory University
• 5:35 PM – 5:45 PM ET

  Tumor Hypoxia on 18F-Fluoromisonidazole Positive Emission Tomography as a Predictor of Distant Metastasis-Free Survival after Chemoradiation for Head and Neck Squamous Cell Carcinoma: A Pooled Analysi
  

  Presenter: Chengcheng Gui, MD – Memorial Sloan Kettering Cancer Center
• 5:45 PM – 5:55 PM ET

  Imaging Metrics and HPV ctDNA Kinetics in a Phase II Immuno-Chemoradiation Trial for Locoregionally Advanced p16+ Oropharynx Cancer
  

  Presenter: Samuel Regan, MD – University of Michigan
• 5:55 PM – 6:05 PM ET

  Chromosomal Instability as a Prognostic Biomarker for Local Failure in Laryngeal Carcinoma Patients Treated with Definitive Radiation in NRG/RTOG 9512
  

  Presenter: Pippa Cosper, MD, PhD – University of Wisconsin Madison
• 6:05 PM – 6:15 PM ET

  Discussant
  

  Discussant: Zain Husain, MD – Southern California Permanente Medical Group